1. Home
  2. GECC vs IVA Comparison

GECC vs IVA Comparison

Compare GECC & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GECC
  • IVA
  • Stock Information
  • Founded
  • GECC 2016
  • IVA 2011
  • Country
  • GECC United States
  • IVA France
  • Employees
  • GECC N/A
  • IVA N/A
  • Industry
  • GECC Finance: Consumer Services
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GECC Finance
  • IVA Health Care
  • Exchange
  • GECC Nasdaq
  • IVA Nasdaq
  • Market Cap
  • GECC 121.9M
  • IVA 117.3M
  • IPO Year
  • GECC N/A
  • IVA 2020
  • Fundamental
  • Price
  • GECC $10.87
  • IVA $2.17
  • Analyst Decision
  • GECC
  • IVA Strong Buy
  • Analyst Count
  • GECC 0
  • IVA 4
  • Target Price
  • GECC N/A
  • IVA $13.25
  • AVG Volume (30 Days)
  • GECC 29.5K
  • IVA 6.4K
  • Earning Date
  • GECC 02-27-2025
  • IVA 09-25-2024
  • Dividend Yield
  • GECC 13.42%
  • IVA N/A
  • EPS Growth
  • GECC N/A
  • IVA N/A
  • EPS
  • GECC 0.65
  • IVA N/A
  • Revenue
  • GECC $39,468,000.00
  • IVA $20,652,523.00
  • Revenue This Year
  • GECC $17.68
  • IVA N/A
  • Revenue Next Year
  • GECC $4.96
  • IVA $361.78
  • P/E Ratio
  • GECC $16.61
  • IVA N/A
  • Revenue Growth
  • GECC 16.86
  • IVA N/A
  • 52 Week Low
  • GECC $9.55
  • IVA $1.53
  • 52 Week High
  • GECC $11.31
  • IVA $4.50
  • Technical
  • Relative Strength Index (RSI)
  • GECC 60.08
  • IVA 39.56
  • Support Level
  • GECC $10.02
  • IVA $2.11
  • Resistance Level
  • GECC $10.80
  • IVA $2.24
  • Average True Range (ATR)
  • GECC 0.34
  • IVA 0.07
  • MACD
  • GECC 0.03
  • IVA 0.01
  • Stochastic Oscillator
  • GECC 79.63
  • IVA 26.58

About GECC Great Elm Capital Corp.

Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. The company seeks to generate current income and capital appreciation through debt and equity investments, including investments in specialty finance businesses. It invests in senior secured and senior unsecured debt instruments, as well as in junior loans and mezzanine debt of middle-market companies and small businesses. The company generates revenue from interest on the debt investments that it holds.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: